9 research outputs found
OncoPrint of genomic alterations in TCGA CRC cases (n = 220) showing mutations of SMAD4, KRAS, NRAS, and BRAF.
<p>OncoPrint of genomic alterations in TCGA CRC cases (n = 220) showing mutations of SMAD4, KRAS, NRAS, and BRAF.</p
Comparison of survival curves in patients with metastatic CRC according to SMAD4 mutation status.
<p>Median OS durations of 29 months (95% CI, 20–48 months) and 56 months (95% CI, 51–63 months) were observed in patients with mutated and wild-type SMAD4, respectively.</p
Demographic and tumor characteristics of CRC patients according to SMAD4 mutation status.
<p>Demographic and tumor characteristics of CRC patients according to SMAD4 mutation status.</p
The prevalence and spectrum of SMAD4 mutations in the MD Anderson study patients and TCGA data.
<p>(A) The prevalence and spectrum of SMAD4 mutations in the study patients who underwent full-length sequencing (n = 49). (B) The prevalence and spectrum of SMAD4 mutations in TCGA data (n = 220 patients).</p
Univariate and multivariate Cox regression analyses of OS in metastatic CRC patients (n = 600).
<p>Univariate and multivariate Cox regression analyses of OS in metastatic CRC patients (n = 600).</p
Comparison of the incidences of SMAD4 mutations across different molecular subtypes.
<p>Comparison of the incidences of SMAD4 mutations across different molecular subtypes.</p
Progression-free survival curves for CRC patients who received anti-EGFR treatment according to SMAD4 mutation status.
<p>All patients were wild-type for KRAS, NRAS, and BRAF genes.</p
Comparison of the incidences of TGF-β pathway mutations across different molecular subtypes.
<p>Comparison of the incidences of TGF-β pathway mutations across different molecular subtypes.</p
OncoPrint showing the distribution of TGF-β mutations across different molecular subtypes in TCGA CRC samples.
<p>OncoPrint showing the distribution of TGF-β mutations across different molecular subtypes in TCGA CRC samples.</p